Article Sidebar
Published:
Jan 10, 2025Keywords:
Article Details
Articles published in the Ghana Medical Journal may not be published elsewhere without the consent of the publishers. Request for consent for reproduction of material published in the Ghana Medical Journal should be addressed to the Editor-in-Chief. The publisher of this Journal reserves the right of copyright of all articles published in the Journal. It should also be understood by all authors that articles approved for publication in the journal are also deemed for publication online by the publisher.
Ghana Medical Journal is an Open Access journal and applies the Creative Commons Attribution (CC BY) license (Creative Commons Attribution License) 4.0 International. See details on the Creative Commons website (https://creativecommons.org/licenses/by/4.0/) to articles and other content published in the Journal.
Main Article Content
A health facility-based assessment of the ancillary benefit for prevention of anaemia at term of intermittent preventive therapy with sulfadoxine-pyrimethamine in pregnancy
Abstract
Objective: This study aims to evaluate the ancillary benefit of intermittent preventive therapy with sulfadoxine-pyrimethamine ( IPTp-SP) in preventing maternal anaemia (MA) among parturient women differentially exposed to the regimen.
Design: A health facility-based retrospective analytical cross-sectional study.
Settings: The study was conducted at the Kade Government Hospital’s maternity/labor suit.
Participants: Data from 2,545 parturient women were abstracted from birth registers.
Statistical analysis: Baseline characteristics were described, and stratified analyses assessed their impacts. Differences in mean mHgbc based on IPTp-SP exposure were determined using one-way ANOVA. An unpaired two-sample t-test evaluated the significance of inter-dose group differences. The bivariable analysis examined crude and adjusted risks of anaemia with differential IPTp-SP exposure.
Main outcome measure: The main outcome measure was the level of mHgbc with varying IPTp-SP exposure.
Results: The overall mean exposure to IPTp-SP was 2.35 (±2.35) doses. Of the women, 5.9% had ‘nil’ exposure, with a mean mHgbc of 9.71 g/dL (±1.6). Among the 75.9% who received 1-3 doses, the mean mHgbc was 10.39 g/dL (±1.3). For the 18.2% who received ≥4 doses, the mean mHgbc was 10.77 g/dL (±1.4). The mHgbc notably rose as the mean doses of IPTp-SP increased. The crude odds ratios (COR) were 1.96 (95% CI: 0.99-3.89, p = 0.06) for ‘nil’ exposure, 1.28 (95% CI: 0.92-1.78, p = 0.16) for 1-3 doses, and 0.59 (95% CI: 0.41-0.84, p = 0.002) for ≥4 doses.
Conclusion: The consistent linear increase in mean mHgbc with higher IPTp-SP doses remains clinically crucial.
